This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case
by Zacks Equity Research
Bayer shares jump after the U.S. Solicitor General backs a Supreme Court review of its Roundup case, adding momentum to its strong 2025 run.
JNJNegative Net Change BAYRYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
by Zacks Equity Research
Pacira BioSciences' iovera shows stronger, longer-lasting relief than RFA in a pilot CLBP study, highlighting its tissue-sparing approach and potential spine-care impact.
PCRXPositive Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
by Ahan Chakraborty
Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.
NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
VRTXPositive Net Change MRNAPositive Net Change CRSPPositive Net Change
biotechs pharmaceuticals
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
by Zacks Equity Research
Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.
REGNNegative Net Change RHHBYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business
by Zacks Equity Research
BHC jumps 11% as Solta Medical acquires Wuhan Shibo Zhenmei, gaining full control of its China aesthetics distribution business.
FOLDPositive Net Change ANIPPositive Net Change CRMDPositive Net Change BHCPositive Net Change
biotechnology biotechs medical pharmaceuticals
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
by Zacks Equity Research
Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.
PFEPositive Net Change NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
by Kinjel Shah
Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.
AZNPositive Net Change BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis
by Zacks Equity Research
J&J gains EU approval for Imaavy, the first FcRn blocker for adults and adolescents with generalized myasthenia gravis.
JNJNegative Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTPositive Net Change
pharmaceuticals
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
by Sundeep Ganoria
Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change PCVXPositive Net Change
biotechs messenger-rna pharmaceuticals vaccines
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi (Revised)
by Zacks Equity Research
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
BMYPositive Net Change JNJNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
by Zacks Equity Research
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
ARCTPositive Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
REGNNegative Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
by Sundeep Ganoria
Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.
PFEPositive Net Change NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus
by Santanu Roy
MBX Biosciences' sharp rally highlights how Zacks' stock recommendations outpaced broader market gains across multiple portfolios.
UNHPositive Net Change JNJNegative Net Change PWRPositive Net Change STXNegative Net Change AXSNegative Net Change CACINegative Net Change CORNegative Net Change MNSTNegative Net Change COHRPositive Net Change NOBLPositive Net Change GTXPositive Net Change MBXPositive Net Change
auto-tires-trucks business-services computers construction consumer-staples insurance medical pharmaceuticals
JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030
by Kinjel Shah
JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.
AZNPositive Net Change JNJNegative Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Buy These 5 Best Value Stocks to Make the Most of P/B Ratio
by Kinjel Shah
Discover five low P/B picks like STNE that are undervalued and show solid growth potential based on value-focused filters.
AXSNegative Net Change GLDDPositive Net Change ENSPositive Net Change STNENegative Net Change KROSPositive Net Change
computers construction insurance pharmaceuticals
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
by Ekta Bagri
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
BMYPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
by Ekta Bagri
Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.
RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
by Ahan Chakraborty
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
PFEPositive Net Change NVOPositive Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
by Zacks Equity Research
NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.
PFEPositive Net Change NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
AstraZeneca or Merck: Which Oncology Giant Has the Edge?
by Kinjel Shah
AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
AZNPositive Net Change MRKPositive Net Change CDTXPositive Net Change SMMTPositive Net Change
pharmaceuticals
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
by Sundeep Ganoria
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
REGNNegative Net Change BEAMPositive Net Change NTLAPositive Net Change
biotechs cell-therapy crispr gene-editing gene-therapy medical pharmaceuticals
Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026
by Bryan Hayes
Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.
LLYNegative Net Change
artificial-intelligence earnings investing large-cap medical oncology-screening pharmaceuticals smart-health
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
by Zacks Equity Research
Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.
PFEPositive Net Change NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
pharmaceuticals